Protagonist Therapeutics Inc (PTGX)
Debt-to-equity ratio
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 560,444 | 336,677 | 302,149 | 294,068 | 216,167 | 215,608 | 243,616 | 267,978 | 301,778 | 300,021 | 329,660 | 357,447 | 259,334 | 279,606 | 169,590 | 167,485 | 62,666 | 79,964 | 95,358 | 84,316 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
March 31, 2024 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $560,444K
= 0.00
The debt-to-equity ratio of Protagonist Therapeutics Inc has consistently been 0.00 across various reporting periods from December 2019 to March 2024. This indicates that the company has not utilized any debt financing to fund its operations or growth activities during this period. A debt-to-equity ratio of 0.00 typically suggests that the company's operations are primarily funded by equity, implying lower financial risk as there is no debt burden to service. It is important to note that while a low debt-to-equity ratio is generally viewed positively, it may also indicate a missed opportunity to leverage debt for potential growth or tax benefits.
Peer comparison
Mar 31, 2024